For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | 487 |
| Cost of revenues | - | 0 | - | -60 |
| Gross loss | - | 0 | - | 547 |
| Research and development | 1,035 | 1,136 | 1,309 | 1,001 |
| Gain (loss) on termination of lease | - | - | - | 1,576 |
| General and administrative | 958 | 1,365 | 1,421 | 3,381 |
| Change in fair value of warrant liabilities | - | 0 | -1 | -831 |
| Total operating expenses | 1,993 | 2,501 | 2,730 | 2,806 |
| Fair value adjustments to bridge notes derivative liability | - | - | - | -1,038 |
| Loss from operations | -1,993 | -2,501 | -2,730 | -2,259 |
| Gain (loss) on extinguishment of debt | 734 | - | - | -22,440 |
| Forward sales contract expense | - | -512 | -5,335 | - |
| Interest income (expense), net | 31 | 0 | 5 | -1,686 |
| Change in fair value of contingent consideration | - | 0 | - | - |
| Other expense, net | -6 | -123 | -135 | - |
| Total other income (expense), net | 759 | -635 | -5,464 | -24,333 |
| Loss before income taxes | -1,234 | -3,136 | -8,194 | -26,592 |
| Provision for income taxes | 6 | 3 | 8 | 12 |
| Net loss | -1,240 | -3,139 | -8,202 | -26,604 |
| Series a preferred stock dividend | - | 8 | - | - |
| Net loss attributable to common stockholders | -1,240 | -3,147 | - | -26,604 |
| Net loss per common share - basic | -0.15 | -0.61 | -0.15 | -4.92 |
| Net loss per common share - diluted | -0.15 | -0.61 | -0.15 | -4.92 |
| Weighted average shares outstanding - basic | 8,226,000 | 5,179,000 | 53,361,000 | 5,410,000 |
| Weighted average shares outstanding - diluted | 8,226,000 | 5,179,000 | 53,361,000 | 5,410,000 |
Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. (ERNA)